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Abstract
Susceptibility to migraine is influenced by a multitude of factors including 
gene-environment and gene-gene interactions. The emerging picture of migraine 
pathogenesis is that it is a complex polygenic and heterogeneous disorder at 
both the population and molecular levels. Causes of migraine are not very clearly 
understood and therefore research into the aetiology of migraine takes several 
different approaches including genetic, pharmacological and biochemical to 
integrate disease based information on multiple levels. Neurotransmitters have 
been implicated in migraine pathogenesis, in particular the excitatory transmitter 
glutamate with supporting evidence from GWAS and genotyping case-control 
studies. The brain contains large amounts of glutamate, a plentiful excitatory 
amino acid neurotransmitter necessary to the integrity of synaptic plasticity 
and memory in CNS functioning, which is highly toxic to neurons if present 
for prolonged periods. Glutamate has been implicated in cortical spreading 
depression (CSD) in animal models and the ingestion of glutamate in the form 
of monosodium glutamate in predisposed individuals can elicit sensitivity and 
migraine-like headache (the MSG Symptom Complex). Comparisons between 
migraine patients and normal controls on biochemical measures in a range 
of biological fluids have shown significant differences between these groups 
particularly in migraineurs with aura. Despite the observation of notable 
biochemical alterations, specific diagnostic markers are lacking. In this review 
we discuss biochemical findings in plasma, platelets, saliva, cerebrospinal fluid, 
and urine that support the conception that a component of glutamate receptor 
disruption may contribute to migraine susceptibility.
Keywords: Migraine; Migraine with aura; Migraine without aura; Glutamate; 
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CSD: Cortical Spreading Depression; MSG: Monosodium 
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FM: Fibromyalgia; CDH: Chronic Daily Headache; CM: Chronic 
Migraine; CH: Cluster Headache; CMF: Chronic Migraine with 
Fibromyalgia; PLTS: Platelets; RBC: Red Blood Cells
Introduction
Glutamate, like serotonin and dopamine is a prominent 
neurotransmitter in the CNS that mediates fast excitatory synaptic 
neurotransmission via ionotropic and metabotropic receptors [1]. 
Glutamatergic receptors are the molecular mediators through which 
glutamate acts and are found in the trigeminovascular system and its 
structures [2,3]. Glutamate is stored intracellularly inside synaptic 
vesicles where the concentration may be as high as 100 millimolars 
and is inactive until released into the synapse [4]. Glutamate is 
believed to be required for cortical spreading depression and to 
activate the trigeminovascular system and central sensitization [5-7] 
is a substrate for various enzymes at glutamatergic synapses and is 
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at a crossroads of metabolic pathways acting as a precursor of the 
inhibitory neurotransmitter GABA and being involved in brain 
energy metabolism and nitrogen homeostasis [8]. There are two 
pathways through which glutamate can be synthesized: the majority is 
synthesised from glutamine deamidation via the enzyme glutaminase 
and to a lesser extent approximately one-third is derived from glucose 
via tricarboxylic acid (TCA) cycle intermediates (α- ketoglutarate) 
and transamination with GABA [9]. In addition to glutamate 
receptors and transporters, there are enzymes, such as glutamine 
synthetase (GS) that control the levels of intracellular glutamate, for 
example through the conversion of glutamate to glutamine [10].
Accumulating data from genetic studies demonstrate that 
migraineurs have a perturbed glutamatergic system, which may be 
reflected in the brain as neuronal hyperexcitability [11]. There is also 
accumulating evidence that glutamate receptors exhibit a modulatory 
effect in migraine mechanisms and glutamate modulating therapies 
have shown promise on migraine symptoms [12]. The glutamatergic 
system in migraine patients may be compromised and this may 
occur as a consequence of polymorphisms in genes that regulate 
glutamatergic signalling. Currently there is only evidence to implicate 
the GRIA3 gene of the AMPA receptor, but time will tell if there are more 
polymorphisms in these or other genes to be identified [13,14]. The 
peripheral metabolism of glutamate which includes the production, 
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storage, expression, trafficking and function of ionotropic glutamate 
receptors and glutamate is just as important as is the neuronal 
component of glutamate in the brain and may also have a bearing on 
migraine. The hypothesis is that migraineurs have a propensity for 
genetically disordered glutamatergic neurotransmission.
Migraine is a multi-system disorder with vascular, inflammatory, 
neurological and biochemical components that culminate in central 
neuronal hyperexcitability, which is the underlining mechanism 
most often targeted in pharmacological intervention [15]. The 
ideal situation for diagnosis and treatment of migraine would be to 
have biomarkers which can reliably distinguish those with disease 
from healthy individuals [16]. The genetic evidence for glutamate’s 
involvement in migraine and our knowledge of its biochemical role 
gives it potential to be such a biomarker for migraine. At present, 
however, the development and adoption of glutamate or glutamate-
related  biomarkers is slow and currently there are no validated 
biomarkers for measuring glutamate pathology in CNS injuries or 
disorders, including migraine [16-18]. More precise characterization 
of the glutamate  molecular-signaling  pathways in glutamatergic 
cells is warranted as a prerequisite for understanding the potential 
involvement of the glutamatergic system in the aetiology of migraine. 
The goal of this short review is to summarize the biochemical findings 
of the neurotransmitter glutamate in migraine to help facilitate 
further research which may enable its use as a migraine biomarker.
Glutamate Biochemical Studies
Monosodium glutamate
Glutamate produced outside of the human body is best known 
as “monosodium glutamate” (MSG) which is sodium salt of glutamic 
acid [19]. MSG is a  well-known  food additive and flavor enhancer 
that has been used for more than 100 years in Asian cuisine due 
to the umami (savory) taste it gives to food [20]. Binding of MSG 
to a specific metabotropic glutamate receptor, different from the 
receptors for sweet, salty, sour, and bitter, is thought to be responsible 
for this fifth gustatory sensation [21]. Aside from being synthesized 
as a food additive, MSG is also naturally occurring at high levels in 
some foods such as tomato and cheese. The human body prefers to 
use  L-glutamic  acid which is the  naturally-occurring  predominant 
form of glutamate. The second form of glutamic acid, 
the D-enantiomeric form D-glutamic acid, is found naturally only in 
the cell walls of certain bacteria [22]. Manufactured/processed MSG 
typically contains L-glutamic acid in addition to the D-enantiomer 
D-glutamic  acid and a mixture of impurities of pyroglutamic acid, 
mono and dichloro propanols and heterocyclic amines [23,24]. 
Further research regarding the impact of D-amino acid metabolism 
with the normal metabolism of L-amino acids is necessary in view of 
the fact that some studies have shown that when D-glutamate is given 
to mice in large doses it can suppress immunological activity [25].
Early reports claimed that MSG may be the cause of headache 
and Alfred Scopp in 1991 published a study “MSG and hydrolyzed 
vegetable protein induced headache: review and case studies” 
questioning the connection between MSG and headache [26]. 
According to this study, MSG, tyramine and aspartame were found to 
be migraine triggers in susceptible individuals [26]. This observation 
is supported by discussion in the published literature of the Chinese 
Restaurant Syndrome (CRS) now better known as the MSG symptom 
complex [27]. MSG symptom complex refers to a triad of symptoms 
first reported in 1968 after ingestion of a Chinese meal [28]. The 
symptoms experienced were described as “numbness at the back 
of the neck and arms gradually radiating to the arms and the back, 
general weakness, and palpitations” and were thought to be brought 
on by ingestion of food rich in MSG in particular Chinese cuisine 
[29]. Based on these observations researchers have investigated the 
potential relationship between MSG and headache and the MSG 
symptom complex in various studies in animals and humans.
MSG injected intravenously into rats has been shown to raise 
intramuscular tissue concentrations of glutamate through activation 
of  N-methyl-D-aspartate  (NMDA) receptors [6,30]. Elevated tissue 
concentrations of glutamate have been shown to contribute to pain 
and sensitivity in certain musculoskeletal pain conditions [31]. Baad-
Hansen et al., 2009 investigated the influence of an oral dose of MSG 
based on each individual subject’s body weight, administered to 14 
young healthy male volunteers and the occurrence of headache, side-
effects,  sensitivity to pressure pain in masseter and temporalis 
muscles, blood pressure and heart rate were assessed [32]. This study 
reported a significant increase in subjects’  self-reported symptoms 
of headache and pericranial muscle tenderness after ingestion of 
MSG, as well as increased systolic blood pressure. Similarly and more 
recently Shimada et al., 2013 [33] conducted a double-blind, placebo-
controlled,  crossover study to look at the effect of MSG intake on 
spontaneous headache. The conclusion reached was that subjects 
consuming MSG had higher systemic levels of glutamate and 
that this is the reason participants were more likely to suffer from 
headache and have accompanying masseter muscle sensitivity. 
Overall, neurotoxicity by MSG has been demonstrated in animals 
and various studies in humans have investigated reports of adverse 
reactions to MSG with high doses however, the symptoms reported 
in these studies are neither persistent nor serious. Consequently, 
the data on the relationship between MSG and migraine headache 
is still inconclusive and a causal relationship has not explicitly been 
identified and further investigation is warranted [27,34-36]. Although 
a subset of the population react adversely to MSG and are termed 
“MSG sensitive individuals” who have experienced adverse reactions 
which include skin rash, tachycardia, migraine headache, depression, 
and seizures, altogether the literature agrees there is inadequate 
evidence to establish MSG as a causative factor of migraine headache 
[23].
Plasma
In the last 30 years, biochemical studies investigating glutamate 
levels in plasma, platelets, CSF and urine of migraine patients have 
reported significantly higher glutamate concentrations particularly in 
patients with migraine with aura. The main source of glutamate is 
from neurons however, in the periphery, plasma glutamate mostly 
derives from freely circulating platelets which accumulate glutamate 
[37]. Blood plasma is the pale yellow liquid portion of blood in which 
blood cells are suspended and nutrients are dissolved, contributing 
55% of the body’s total blood volume [38].
Thus far, five studies out of seven have reported higher plasmatic 
levels of glutamate in migraine patients between and during attacks 
with the study by Alam et al., 1998 [39] having the largest sample 
size consisting of 80 migraine with aura (MA), 9 migraine without 
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Reference Migraine Classification Controls/Cases Total Sample Size Cases Sample & Levels
(Ferrari et al., 1990) [75] (ICHD-I, 1988) [76] Controls: 9 40 Plasma
MA: 10 ↑
MO: 21 ↑
TH: 9 =
(Martinez et al., 1993) [44] (ICHD-I, 1988) [76] Controls: 21 27 Plasma : CSF
MA: 11 ↓↑:
MO: 16 ↓↑:
(Cananzi et al., 1995) [54] (ICHD-I, 1988) [76] Controls: 19 57 Plasma : PLTS
MA: 32 =↑:
MO: 25 ↑: =
(Deufemia et al., 1997) [45] (ICHD-I, 1988) [76] Controls: 16 34 Plasma : RBCs
MA: 15 ↓: =
MO: 19 ↓: =
(Alam et al., 1998) [39] (ICHD-I, 1988) [76] Controls: 62 103 Plasma
MA: 80 ↑
MO: 9 ↑
TH: 14 ↑
(Vaccaro et al., 2007) [55] (ICHD-II, 2004) [77] Controls: 20 50 Plasma : PLTS
MA: 25 ↑↑:
MO: 25 ↑↑:
(Ferrari et al., 2009) (78) (ICHD-II, 2004) [77] Controls: 24 24 Plasma
MO: 24 ↑
(Dandrea et al., 1991) [53] (ICHD-I, 1988) [76] Controls: 17 98 PLTS
MA: 24 ↑
MO: 22 =
TH: 15 =
CH: 37 =
(Zukerman, 1993) [62] (ICHD-I, 1988) [76] Controls: N/A 10 CSF
MA: 6 ↑
MO: 4 ↑
(Gallai et al., 2003) [63] (Silberstein,1996) [79] Controls: 20 25 CSF
CDH: 10 ↑
CDH - medicated: 15 ↑
(Peres et al., 2004) [64] (Silberstein, 1996) [79] Controls: 20 20 CSF
CMF: 12 ↑
CM: 8 ↑
(Vieira et al., 2007) [65] (ICHD-II, 2004) [77]
Controls: 19 19 CSF
CM: 5 ↓
CM - NSAIDS: 8 ↓
CM - Tryptans: 6 ↓
(Ragginer et al., 2012) [67] (ICHD-II, 2004) [77] Controls: 48 48 Urine
MA: 48 ↑
Table 1: Biochemical studies of Glutamate in migraine patients and controls.
CDH = Chronic Daily Headache; CH = Cluster Headache; CMF = Chronic Migraine with Fibromyalgia; CM = Chronic Migraine; CSF = Cerebrospinal fluid; MA = 
Migraine with aura; MO = Migraine without aura; PLTS = Platelets; RBC = Red blood cells; TH = Tension ↑Ic Headache; Rease; ↓Decrease; = Unchanged.
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aura (MO) and 14 Tension Headache (TH) patients (Table 1). 
The largest sample size was 103 and the smallest 24, the average 
sample size in the seven studies using plasma as sample was 48, 
showing a range of studies with various capabilities to detect 
alterations in glutamate metabolism. Moreover, plasma glutamate 
is likely to be linked to the platelet glutamate storage function, 
and individual differences in this mechanism may add additional 
variation to observed glutamate levels [40,41]. Factors which can 
further confound the accurate reporting of plasma glutamate levels 
include differences in experimental procedures, such as different 
concentrations of inducers, centrifugation time and pharmaceutical 
substances produced by different manufacturers, different timing 
of blood sampling (time of day, menstrual cycle, time passed since 
the last attack,  fasting/non-fasting),  blood-drawing  and  sample-
handling  protocols (venipuncture-induced  platelet activation, body 
position, blood sample device: open system/vacutainer, operators’ 
experience, time of stasis), patient drug history and diet [42,43].
Two out of the seven studies reported lower levels of glutamate, 
these included a study by Martinez et al., 1993 [44] and a study by 
Deufemia et al., 1997 [45]. Martinez et al., 1993 [44] considered the 
levels of glutamic and aspartic acid in both plasma and CSF in patients 
with MA and MO relative to a group of controls suffering from 
stress. Despite reporting lower plasma levels, Martinez et al., 1993 
simultaneously reported higher CSF glutamate in migraineurs which 
led the authors to conclude there may be an excess of neuroexcitatory 
amino acids in the central nervous system which may promote a 
state of neuronal hyperexcitability in migraine patients. Deufemia et 
al., 1997 demonstrated lower  plasma-glutamate  levels in paediatric 
migraineurs than in controls and concurrently reported a significantly 
higher erythrocyte to plasma-glutamate ratio [45]. Differences in the 
results may be explained by the nature of the control group in both 
studies which was composed of patients under stress in the Martinez 
study and a group of paediatric controls in the Deufemia study.
The sum of these studies suggest that plasma glutamate could serve 
as a diagnostic tool for monitoring disease status in migraine patients 
and as a biomarker of response to treatment however more studies 
utilizing the latest diagnostic criteria are needed to make a more 
solid conclusion and develop accurate and standardised sampling. 
These findings do support a link between high plasma glutamate 
levels in migraine patients and cortical neuronal hyperexcitability 
which may be mediated via NMDA-glutamatergic transmission and 
may be connected with the pathobiology of migraine. Additionally, 
increased plasma levels of glutamate have been reported in some 
neuropsychiatric disorders in which glutamate excitotoxicity is 
thought to play a role in their pathophysiology, including epilepsy 
[46], Alzheimer’s disease [47] and amyotrophic lateral sclerosis [48].
Platelets
Platelets are the primary source of neurotransmitters in human 
blood [49]. The accessibility of platelets has made them a viable 
cellular tool with which to study the aetiology of neurological 
disorders. Platelets have been considered a useful model for studying 
glutamatergic dysfunction and neurological disorders because they 
possess high-affinity glutamate transporters similar to glutamatergic 
neurons and contain  platelet-dense  granules that store and release 
the neurotransmitter glutamate [40,50] through similar pathways 
to those described in the brain. The rationale for investigating 
peripheral sources of glutamate is that platelet glutamate metabolism 
may contribute to the accumulation of glutamate in the brain and 
its vasculature through the blood brain barrier and hence peripheral 
levels of glutamate/glutamine may correlate with those of the central 
nervous system [51]. In addition platelets possess many molecules 
and receptors which have functional similarities with neuronal 
elements and endothelial cells, for example the up-taking, storing and 
releasing of neurotransmitters such as glutamate, serotonin, GABA 
and dopamine, through expression of their specific receptors and/or 
transporters. These functions may play a role in platelet activation 
and/or aggregation and hence platelets have been used as surrogate 
models for the investigation of peripheral neurotransmitter function 
[52].
Three studies have evaluated glutamate levels in platelets (Table 
1)  [53-55].  In each study, platelets were isolated from a sample of 
whole blood, with a minimum of 8mL and a maximum of 25mL, 
collected after overnight fasting from the antecubital vein of each 
study participant. In every study platelet-rich plasma (PRP) was the 
portion of plasma used to determine platelet counts and from which 
the platelet-rich pellet was harvested. Cananzi et al., 1999 found that 
migraine with aura patients had higher platelet levels than migraine 
without aura patients [54]. D’andrea et al., 1991 measured platelet 
glutamate, aspartate and glycine levels in groups of patients with 
migraine with aura, migraine without aura, tension headache and 
cluster headache [53]. Glutamate, aspartate and glycine levels were 
reported to be highest in migraine with aura patients in this study. 
Vaccaro et al., 2007 in addition reported that platelet glutamate 
uptake, assessed as 3H-glutamate intake, was increased in MA, while 
it was reduced in MO with respect to the control group [55]. These 
studies were consistent, all reporting higher levels of glutamate in the 
platelets of the MA group. Different authors have suggested there 
may be a glutamate metabolic profile specific to a migraine phenotype 
suggesting unique pathophysiological characteristics that may 
explain the observed differences between the two types of migraine 
MA and MO.
Saliva
The justification for utilizing saliva as a fluid for evaluating 
neurotransmitter function is that as fluid saliva is stable and easy to 
obtain and the salivary glands are innervated by the nerve terminals 
of the trigeminovascular system [56]. These nerves innervate the 
mucosal bucca (buccal nerve) and the parotid gland (from the 
mandibular nerve, parotid branches convey secretomotor fibers to 
the gland) [57]. The advantage of using saliva to assay central nervous 
system function is that it is non-invasive to collect and it contains a 
wide array of neuropeptides that might highlight certain clues about 
the pathophysiology of neurological disease [58]. There is one study 
to date that has evaluated free amino acids in saliva of patients with 
migraine and found these to be elevated relative to controls [59]. 
Rajda et al., 1999 tested the saliva of 23 migraineurs without aura and 
14 migraineurs with aura and 20 healthy controls [59]. The amino 
acids tested glutamic acid; serine, glycine, arginine, and tyrosine were 
all found significantly elevated in the saliva samples of both groups 
of migraineurs relative to the control group. These results are in line 
with previous studies investigating glutamate levels in plasma and 
cerebrospinal fluid supporting that a dysfunction of the glutamatergic 
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brain metabolism may exist in migraine. More studies using saliva 
as a sample are needed to ascertain its potential as a fluid to detect 
metabolic abnormalities.
Cerebrospinal fluid
Cerebrospinal fluid (CSF) has been proposed as a source 
of biomarkers because it is within the  blood-brain barrier and 
neurotransmitter levels in CSF may correspond to those in the 
ventricular system. Therefore, CSF from lumbar puncture might 
accurately reflect  glutamate-mediated  excitotoxicity in the CNS 
[60]. The earliest study investigating CSF as a source of biomarkers 
in migraine was by Kovacs et al., 1989 measuring homovanillic acid 
(HVA) and  5-hydroxyindoleacetic  acid  (5-HIAA)  concentrations, 
CSF pressure, total protein content and protein fractions of MA and 
MO patients as well as controls [61]. That study found an increased 
5- HIAA level in migraineurs compared to controls. Since then five 
independent studies [44,62-65] have investigated glutamate levels in 
CSF of migraine patients with results showing migraine patients have 
a significant increase in CSF glutamate levels compared to controls. 
Martinez et al., 1993 [44] identified higher concentrations of glutamate 
in CSF and concluded that high levels of glutamate in the CSF may 
participate in triggering of attacks by contributing to a state of 
neuronal hyperexcitability. The fact that both amino acids glutamate 
and aspartic acid have been  co-involved  in the pathophysiology of 
epilepsy and ischemic and hypoglycemic neuronal death is further 
evidence to support the concept that they may promote a state of 
central neuronal hyperexcitability [44]. Similarly a study by Rothrock 
et al., 1995 [66] found high levels of amino acids (glycine, taurine, 
glutamine) in CSF in migraine patients and a study by Zukerman 
et al., 1993 [62] identified similar results but in a smaller cohort of 
patients.
The study by Peres et al., 2004 [64] used Silberstein classification 
criteria and chronic daily headache patients. This study differed to 
the others as they included migraine patients with and without 
fibromyalgia, a muscular condition  co-morbid  with migraine. 
Fibromyalgia (FM) is a common syndrome of musculoskeletal pain 
and fatigue, which occurs mostly among middle-age women. Peres 
et al., 2004 demonstrated CSF glutamate to be significantly higher in 
migraine patients with fibromyalgia compared to migraine patients 
without fibromyalgia.
The study by Gallai et al., 2003 [63] and Vieira et al., 2007 [65] 
considered the influence of different acute medications on the levels 
of glutamate in CSF. In both these studies patients were divided into 
different treatment groups either using or not using medication. 
Gallai et al., 2003 [63] subdivided patients into two groups, Group 
1 chronic daily headache (CDH) patients without analgesic overuse 
(n = 10) and Group 2 medication overuse patients (n = 15). The 
results of this study indicated that both treatment groups of CDH 
patients with and without analgesic overuse had significantly higher 
CSF glutamate levels than the control group but that there was no 
difference between the two treatment groups, indicating the use of 
acute medications did not influence glutamate levels overall. As the 
authors did not observe high levels of glutamate in healthy controls, 
they concluded that the high level of glutamate in migraine patients 
may represent a biochemical marker of neuronal hyperexcitability.
Vieira et al., 2007 [65] determined CSF glutamate levels of chronic 
migraine patients and found that patients overusing triptans had 
significantly lower CSF glutamate levels than in non-over users but 
CSF glutamate levels were still significantly higher than in healthy 
controls suggesting the glutamatergic system is likely to be altered 
in the migraine brain. The study by Vieira et al., [65] considered 
chronic migraine (CM) patients divided into the following groups: 
Group 1 comprised patients overusing analgesics (NSAIDs); Group 
2 comprised patients not overusing medications; and Group 3 
comprised patients overusing triptans. Vieira et al., 2007 found 
that CM patients in all three treatment groups showed higher CSF 
glutamate levels when compared with control subjects. No difference 
was found between Group 1 patients overusing analgesics (NSAIDs) 
compared to Group 2 those not overusing. However Group 3 patients 
overusing triptans had lower glutamate levels in CSF when compared 
to Group 2 non-overuse patients, though levels were not significantly 
different to Group 1 patients. The authors suggest the decrease of 
glutamate in CSF in the Group 3 patients overusing triptans may be 
connected with the action of triptans as glutamate levels were found 
to be lower after triptan treatment. These data suggest, although 
indirectly, the involvement of excitatory amino acids in central 
nociception in migraine patients and that inhibiting excitatory amino 
acid transmission in central neuronal circuits invol secretomotor 
ved in the processing of nociceptive information could be a route to 
follow for improved treatments.
Although analysis of glutamate levels in CSF is concordant with 
five out of five studies reporting the same result it is important to point 
out that the sample size in each of the studies using CSF was small 
in comparison to studies performed with other fluids. At present no 
specific characteristic or biochemical marker has been consistently 
recognized in affected individuals and therefore future replications 
of these studies will be needed to confirm and strengthen the power 
of these findings. Nevertheless the identification of biochemical and 
genetic mechanisms that control the homeostatic milieu is essential 
to sustained progress in migraine research.
Urine
In 2012 a study by Ragginer et al. [67] reported a significant 
decrease in the urinary glutamate levels of female migraineurs 
with respect to healthy controls, a result which was associated with 
a 4.04-fold higher risk for migraine. The authors hypothesized that 
migraine patients are more prone to suffer metabolic dysfunctions 
and consequently in addition to investigating glutamatergic 
homeostasis in the urine concomitantly investigated parameters of 
insulin and lipid metabolism, inflammatory and anthropometric 
parameters. Commercial ELISA kits and Roche analysers were used 
for determining urinary glutamate levels and various glucose and 
lipid measurements. Migraine has been associated with metabolic 
dysfunctions; in particular, regarding the insulin- and  glucose-
metabolism [68,69]. In this study, however, no significant correlation 
was identified in the urinary glutamate levels and metabolic and 
anthropometric parameters in migraineurs. This is the only study so 
far evaluating glutamate in urine as a sample, but it shows that urine 
may have potential as a source of glutamate biomarkers for migraine. 
Analysis of metabolites obtained from different body fluids can help 
inform the course and progression of a disease, but more complete 
descriptions of the biochemical irregularities must first be established 
before urine can be used in migraine management.
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Glutamate pharmacotherapy
Current migraine therapies work at differing efficacies and often 
have several side-effects; therefore more safe and effective treatment 
options for migraine are a high priority for future research. This is 
because migraine is a multifactorial disorder caused by several factors 
and genetic polymorphisms that together contribute to the variety of 
symptoms and triggers reported by migraineurs [15]. Consequently 
gaining an in depth understanding of the genotypic profile of 
migraineurs is an active area of research that is necessary to improve 
the effectiveness of migraine treatment. Given the broad phenotypic 
expressivity of migraine and variable patient response and presence 
of co-morbidities, a pharmacological repertoire is necessary to target 
the multitude of symptoms exhibited by different migraine patients.
As mentioned above, genetic studies have implicated 
glutamate in migraine pathogenesis [11,13,14]. Deficiency in 
glutamatergic neurotransmission due to genetic mutation in any 
of the gene constituents of the glutamatergic system may result in 
a disturbed balance of synaptic activity and may play a key role in 
the pathophysiology of migraine. Many studies have examined 
pharmacological treatment variation in relation to genetically 
different populations and seek to evaluate the association of 
specific gene polymorphisms to patient response to medication. 
Pharmacogenomics, the hybrid union of pharmacology and genetic 
research, is an expanding discipline that addresses how diseases of 
different genetic make-up respond to treatments. It holds promise in 
the future to design more efficacious pharmaceutical treatments to 
address the specific needs of individual patients based on their genetic 
profile and has already had some notable successes in fields such as 
cancer treatment.
Research into the peripheral metabolism of glutamate, its 
agonists and antagonists has provided the substrate for the 
development of focused modulators of the glutamatergic system. 
Glutamatergic receptors NMDA, AMPA, ka are all potential targets 
for the development of modulators. Preclinical experiments with 
glutamate antagonists have provided experimental evidence for 
pursuing modulators in the treatment of migraine and support the 
hypothesis that blocking glutamate receptor subtypes is a potential 
logical approach. Modulators that have undergone preclinical 
development for the treatment of migraine include BGG492, 
LY293558, LY466195, and ADX10059 [70-73]. Modulators of the 
glutamatergic system already in clinical use include drugs topiramate, 
memantine, ketamine and BoNTA. Such compounds may benefit the 
patient in situations where other regimens have been unsuccessful. 
The advantage of targeting the glutamatergic system is that if 
offers a neurally based  non-vasoactive  approach that can bypass 
the vasoconstrictive  side-effects  that currently plague acute  anti-
migraine therapies [74].
A holistic understanding of the specific receptors and/or cellular 
signalling mechanisms and how drugs affect the functioning of 
neurons in the nervous system is required to make drug design 
targeted and effective. There are some clear difficulties however with 
the use of glutamatergic modulators that must be overcome, such as 
neurotoxicity.  Well-designed  clinical studies using larger and well 
stratified migraine cohorts will further our current understanding of 
the role of modulators of the glutamatergic system in migraine and 
aid in the development of therapies to prevent and/or abort migraine 
attacks.
Conclusion
Migraine is a complex disorder marked by variability in severity 
and clinical phenotypic expression. The majority of the biochemical 
evidence suggests that glutamate levels play a role in the pathogenesis 
of migraine. The biochemical studies performed to date have 
highlighted that glutamate levels are elevated in migraineurs as 
detected in a range of biological fluids including plasma, platelets, 
saliva, CSF and urine. Although the studies typically involved a 
small number of subjects, they offer insight into the biochemical 
phenotype of migraine and are concordant with recent genetic 
findings implicating the neurotransmitter glutamate in migraine 
pathogenesis. Moreover analyses of glutamate in plasma and platelets 
have revealed that the uptake and release of glutamate is altered in 
migraine patients, particularly those with aura. The most supported 
result is the elevated glutamate levels in CSF reported in five out of 
five studies, indicating an excess of neuroexcitatory amino acids 
in the central nervous system that could reflect a state of neuronal 
hyperexcitability.
Collectively, these studies indicate that there may be a 
biochemical abnormality of glutamate in migraine and therefore 
treatments modulating this system are plausible candidates to be 
pursued. Dysregulation of brain glutamate systems through changes 
in glutamate mechanisms may result in symptoms of migraine. 
Although a clear biochemical cause is lacking, biochemical evidence 
supports the involvement of neurotransmitters serotonin, dopamine 
and glutamate in migraine aetiology. Follow up studies into the 
underlining disrupted mechanism of glutamatergic metabolism and 
activity may highlight more consistent markers. Newer studies with 
larger numbers of subjects and utilizing more modern laboratory 
equipment and methods are needed to more thoroughly establish 
the potential involvement of glutamate and other biochemical 
metabolites in migraine. Biochemical approaches interwoven with 
studies in other disciplines are necessary to discern the biochemical 
milieu and to identify the proper utility of glutamate and a migraine 
biomarker. Creative approaches are needed to complement current 
research strategies to continue to unravel piece by piece the molecular, 
genetic and biochemical substrate of migraine.
References
1. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and 
neurodegeneration. Pflugers Arch. 2010; 460: 525-542.
2. Sahara Y, Noro N, Iida Y, Soma K, Nakamura Y. Glutamate receptor subunits 
GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J 
Neurosci. 1997; 17: 6611-6620.
3. Storer RJ, Goadsby PJ. Trigeminovascular nociceptive transmission 
involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate 
receptors. Neuroscience. 1999; 90: 1371-1376.
4. McKenna MC. The glutamate-glutamine cycle is not stoichiometric: Fates of 
glutamate in brain. J Neurosci Res. 2007; 85: 3347-3358.
5. Charles AC, Baca SM. Cortical spreading depression and migraine. Nat Rev 
Neurol. 2013; 9: 637-644.
6. Cairns BE, Gambarota G, Svensson P, Arendt-Nielsen L, Berde 
CB. Glutamate-inducedsensitization of rat masseter muscle fibers. 
Neuroscience. 2002; 109: 389-399.
Austin J Clin Neurol 2(9): id1079 (2015)  - Page - 07
Griffiths LR Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
7. Costa C, Tozzi A, Rainero I, Cupini LM, Calabresi P, Ayata C, et al. Cortical 
spreading depression as a target for anti-migraine agents. J Head Pain. 2013; 
14: 62.
8. Kelly A, Stanley CA. Disorders of glutamate metabolism. Mental retardation 
and developmental disabilities research reviews. 2001; 7: 287-295.
9. Prusiner SB. Disorders of glutamate metabolism and neurological dysfunction. 
Annu Rev Med. 1981; 32: 521-542.
10. Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001; 65: 1-105.
11. Campos F, Sobrino T, Perez-Mato M, Rodriguez-Osorio X, Leira R, Blanco M, 
et al. Glutamate oxaloacetate transaminase: A new key in the dysregulation 
of glutamate in migraine patients. Cephalalgia. 2013; 33: 1148-1154.
12. Chan K, Maassen Van Den Brink A. Glutamate receptor antagonists in the 
management of migraine. Drugs. 2014; 74: 1165-1176.
13. Formicola D, Aloia A, Sampaolo S, Farina O, Diodato D, Griffiths LR, et al. 
Common variants in the regulative regions of GRIA1 and GRIA3 receptor 
genes are associated with migraine susceptibility. BMC Med Genet. 2010; 
11: 103.
14. Maher BH, Lea R, Follett J, Cox HC, Fernandez F, Esposito T, et 
al. Association of a GRIA3 gene polymorphism with migraine in an 
Australian case-control cohort. Headache. 2013; 53: 1245-1249.
15. Gasparini CF, Sutherland HG, Griffiths LR. Studies on the Pathophysiology 
and Genetic Basis of Migraine. Curr Genomics. 2013; 14: 300-315.
16. De Vries B, Haan J, Frants RR, Van den Maagdenberg AMJM, Ferrari MD. 
Genetic Biomarkers for Migraine. Headache. 2006; 46: 1059-1068.
17. Edvinsson L. Neuronal signal substances as biomarkers of migraine. 
Headache. 2006; 46: 1088-1094.
18. Harrington MG. Cerebrospinal fluid biomarkers in primary headache 
disorders. Headache. 2006; 46: 1075-1087.
19. Jinap S, Hajeb P. Glutamate. Its applications in food and contribution to 
health. Appetite. 2010; 55: 1-10.
20. Chaudhari N, Roper SD. Molecular and physiological evidence for glutamate 
(umami) taste transduction via a G protein-coupled receptor. Ann N Y Acad 
Sci. 1998; 855: 398-406.
21. Chaudhari N, Pereira E, Roper SD. Taste receptors for umami: the case for 
multiple receptors. Am J Clin Nutr. 2009; 90: 738S-742S.
22. Win DT. MSG–Flavor Enhancer or Deadly Killer. Au J T. 2008; 12: 43-49.
23. Freeman M. Reconsidering the effects of monosodium glutamate: a literature 
review. J Am Acad Nurse Pract. 2006; 18: 482-486.
24. Ackroff K, Sclafani A. Flavor preferences conditioned by oral monosodium 
glutamate in mice. Chem Senses. 2013; 38:745-758.
25. Rundlett KL, Armstrong DW. Evaluation of free D-glutamate in processed 
foods. Chirality. 1994; 6: 277-282.
26. Scopp AL. MSG and hydrolyzed vegetable protein-induced headache - 
review and case-studies. Headache. 1991; 31: 107-110.
27. Morselli PL, Garattin S. Monosodium glutamate and chinese restaurant 
syndrome Nature.1970; 227: 611-612.
28. Ghadimi H, Kumar S, Abaci F. Monosodium glutamate ingestion. Biochemical 
explanation of chinese restaurant syndrome. Biochem Med. 1971; 5: 447.
29. Schaumburg HH, Byck R, Gerstl R, Mashman JH. Monosodium L-glutamate: its 
pharmacology and role in the Chinese restaurant syndrome. Science. 1969; 
163: 826-828.
30. Cairns BE, Dong X, Mann MK, Svensson P, Sessle BJ, Arendt-Nielsen L, et 
al. Systemic administration of monosodium glutamate elevates intramuscular 
glutamate levels and sensitizes rat masseter muscle afferent fibers. 
Pain. 2007; 132: 33-41.
31. Alfredson H, Ljung BO, Thorsen K, Lorentzon R. In vivo investigation of 
ECRB tendons with microdialysis technique--no signs of inflammation but 
high amounts of glutamate in tennis elbow. Acta Orthop Scand. 2000; 71: 
475-479.
32. Baad-Hansen L, Cairns BE, Ernberg M, Svensson P. Effect of systemic 
monosodium glutamate (MSG) on headache and pericranial muscle 
sensitivity. Cephalalgia. 2009; 30: 68-76.
33. Shimada A, Cairns BE, Vad N, Ulriksen K, Pedersen AM, Svensson P, et al. 
Headache and mechanical sensitization of human pericranial muscles after 
repeated intake of monosodium glutamate (MSG). J Headache Pain. 2013; 
14: 2.
34. Schaumbu H, Byck R, Gerstl R, Mashman JH. Monosodium L-Glutamate its 
pharmacology and role in chinese restaurant syndrome. Science. 1969; 163: 
826-828.
35. Zanda G, Francios P, Tognoni G, Rizzo M, Standen SM, Morselli PL, 
et al. Double-blind study on effects of monosodium glutamate in man. 
Biomedicine. 1973; 19: 202-204.
36. Geha RS, Beiser A, Ren C, Patterson R, Greenberger PA, Grammer LC, et al. 
Multicenter, double-blind, placebo-controlled, multiple-challenge evaluation of 
reported reactions to monosodium glutamate. J Allergy Clin Immunol. 2000; 
106: 973-980.
37. Brand T, Anderson GM. The Measurement of Platelet-Poor Plasma Serotonin: 
A Systematic Review of Prior Reports and Recommendations for Improved 
Analysis. Clin Chem. 2011; 57: 1376-1386.
38. Yawn DH. Plasma in Encyclopaedia Britannica 2015.
39. Alam Z, Coombes N, Waring RH, Williams AC, Steventon GB. Plasma levels 
of neuroexcitatory amino acids in patients with migraine or tension headache. 
J Neurol Sci. 1998; 156: 102-106.
40. Mangano RM, Schwarcz R. The human-platelet as a model for the 
glutamatergic neuron – platelet uptake of L-glutamate. J Neurochem. 1981; 
36: 1067-1076.
41. Tremolizzo L, DiFrancesco JC, Rodriguez-Menendez V, Sirtori E, Longoni 
M, Cassetti A, et al. Human platelets express the synaptic markers VGLUT1 
and 2 and release glutamate following aggregation. Neurosci Lett. 2006; 404: 
262-265.
42. Morgadinho MT, Fontes Ribeiro CA, Macedo TR. Influence of the sample 
preparation method on the serotonin determination in plasma and platelets. 
Biomed Chromatogr. 2004; 18: 739-744.
43. D’Andrea G, Cananzi AR, Perini F, Hasselmark L. Platelet models and their 
possible usefulness in the study of migraine pathogenesis. Cephalalgia. 1995; 
15: 265-271.
44. Martínez F, Castillo J, Rodríguez JR, Leira R, Noya M. Neuroexcitatory 
amino acid levels in plasma and cerebrospinal fluid during migraine attacks. 
Cephalalgia. 1993; 13: 89-93.
45. D’Eufemia P, Finocchiaro R, Lendvai D, Celli M, Viozzi L, Troiani P, et al. 
Erythrocyte and plasma levels of glutamate and aspartate in children affected 
by migraine. Cephalalgia. 1997; 17: 652-657.
46. Rainesalo S, Keränen T, Palmio J, Peltola J, Oja SS, Saransaari P. Plasma 
and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res. 
2004; 29: 319-324.
47. Miulli DE, Norwell DY, Schwartz FN. Plasma concentrations of glutamate and 
its metabolites in patients with Alzheimer’s disease. J Am Osteopath Assoc. 
1993; 93: 670-676.
48. Iłzecka J, Stelmasiak Z, Solski J, Wawrzycki S, Szpetnar M. Plasma amino 
acids concentration in amyotrophic lateral sclerosis patients. Amino Acids. 
2003; 25: 69-73.
49. Tyce GM. Origin and metabolism of serotonin. J Cardiovasc Pharmacol. 
1990; 16: S1-7.
50. D’Andrea G, Cananzi AR, Perini F, Hasselmark L. Platelet models and their 
possible usefulness in the study of migraine pathogenesis. Cephalalgia. 
1995; 15: 265-271.
Austin J Clin Neurol 2(9): id1079 (2015)  - Page - 08
Griffiths LR Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
51. Malmgren R, Hasselmark L. The platelet and the neuron: two cells in focus in 
migraine. Cephalalgia. 1988; 8: 7-24.
52. Begni B, Tremolizzo L, D’Orlando C, Bono MS, Garofolo R, Longoni M, et al. 
Substrate-induced modulation of glutamate uptake in human platelets. Br J 
Pharmacol. 2005; 145: 792-799.
53. D’Andrea G, Cananzi AR, Joseph R, Morra M, Zamberlan F, Ferro Milone 
F, et al. Platelet glycine, glutamate and aspartate in primary headache. 
Cephalalgia. 1991; 11: 197-200.
54. Cananzi AR, D’Andrea G, Perini F, Zamberlan F, Welch KM. Platelet and 
plasma levels of glutamate and glutamine in migraine with and without aura. 
Cephalalgia. 1995; 15: 132-135.
55. Vaccaro M, Riva C, Tremolizzo L, Longoni M, Aliprandi A, Agostoni E, et 
al. Platelet glutamate uptake and release in migraine with and without aura. 
Cephalalgia. 2007; 27: 35-40.
56. Nicolodi M, Del Bianco E. Sensory neuropeptides (substance P, calcitonin 
gene-related peptide) and vasoactive intestinal polypeptide in human saliva: 
their pattern in migraine and cluster headache. Cephalalgia. 1990; 10: 39-50.
57. Holsinger FC, Bui D. Anatomy, Function, and Evaluation of the Salivary 
Glands. In: Myers E, Ferris R, editors. Salivary Gland Disorders: Springer 
Berlin Heidelberg. 2007: 1-16.
58. Fischer HP, Eich W, Russell IJ. A possible role for saliva as a diagnostic 
fluid in patients with chronic pain. Semin Arthritis Rheum. 1998; 27: 348-359.
59. Rajda C, Tajti J, Komoróczy R, Seres E, Klivényi P, Vécsei L. Amino acids in 
the saliva of patients with migraine. Headache. 1999; 39: 644-649.
60. Stover JF, Pleines UE, Morganti-Kossmann MC, Kossmann T, Lowitzsch 
K, Kempski OS. Neurotransmitters in cerebrospinal fluid reflect pathological 
activity. Eur J Clin Invest. 1997; 27: 1038-1043.
61. Kovács K, Bors L, Tóthfalusi L, Jelencsik I, Bozsik G, Kerényi L, et al. 
Cerebrospinal fluid (CSF) investigations in migraine. Cephalalgia. 1989; 9: 
53-57.
62. Zukerman E, Minatti-Hannuch SN, Mazzacoratti MGN, dos Reis Filho JB, 
Cavalheiro EA. Cerebrospinal fluid neurotransmitter amino acids in migraine. 
Cephalalgia. 1993; 13: 92.
63. Gallai V, Alberti A, Gallai B, Coppola F, Floridi A, Sarchielli P. Glutamate and 
nitric oxide pathway in chronic daily headache: evidence from cerebrospinal 
fluid. Cephalalgia. 2003; 23: 166-174.
64. Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber 
MH. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia. 
2004; 24: 735-739.
65. Vieira DS, Naffah-Mazzacoratti Mda G, Zukerman E, Senne Soares CA, 
Cavalheiro EA, Peres MF. Glutamate levels in cerebrospinal fluid and triptans 
overuse in chronic migraine. Headache. 2007; 47: 842-847.
66. Rothrock JF, Mar KR, Yaksh TL, Golbeck A, Moore AC. Cerebrospinal fluid 
analyses in migraine patients and controls. Cephalalgia. 1995; 15: 489-493.
67. Ragginer C, Lechner A, Bernecker C, Horejsi R, Möller R, Wallner-Blazek M, 
et al. Reduced urinary glutamate levels are associated with the frequency of 
migraine attacks in females. Eur J Neurol. 2012; 19: 1146-1150.
68. Rainero I, Limone P, Ferrero M, Valfrè W, Pelissetto C, Rubino E, et al. 
Insulin sensitivity is impaired in patients with migraine. Cephalalgia. 2005; 
25: 593-597.
69. Cavestro C, Rosatello A, Micca G, Ravotto M, Marino MP, Asteggiano G, et 
al. Insulin metabolism is altered in migraineurs: a new pathogenic mechanism 
for migraine? Headache. 2007; 47: 1436-1442.
70. Weiss B, Alt A, Ogden AM, Gates M, Dieckman DK, Clemens-Smith A, et 
al. Pharmacological characterization of the competitive GLUK5 receptor 
antagonist decahydroisoquinoline LY466195 in vitro and in vivo. J Pharmacol 
Exp Ther. 2006; 318: 772-781.
71. Gomez-Mancilla B, Brand R, Jurgens TP, Gobel H, Sommer C, Straube A, et 
al. Randomized, multicenter trial to assess the efficacy, safety and tolerability 
of a single dose of a novel AMPA receptor antagonist BGG492 for the 
treatment of acute migraine attacks. Cephalalgia. 2014; 34: 103-113.
72. Marin JC, Goadsby PJ. Glutamatergic fine tuning with ADX-10059: a novel 
therapeutic approach for migraine? Expert Opin Investig Drugs. 2010; 19: 
555-561.
73. Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, 
et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-
tolerated in acute migraine. Cephalalgia. 2004; 24: 596-602.
74. Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new 
approaches. Curr Treat Options Neurol. 2011; 13: 1-14.
75. Ferrari MD, Odink J, Bos KD, Malessy MJ, Bruyn GW. Neuroexcitatory 
plasma amino acids are elevated in migraine. Neurology. 1990; 40: 1582-
1586.
76. [No authors listed]. Classification and diagnostic criteria for headache 
disorders, cranial neuralgias and facial pain. Headache Classification 
Committee of the International Headache Society. Cephalalgia. 1988; 8 
Suppl 7: 1-96.
77. IHS. The International classification of headache disorders, 2nd edition. 
Cephalalgia. 2004; 24: 1-160.
78. Ferrari A, Spaccapelo L, Pinetti D, Tacchi R, Bertolini A. Effective prophylactic 
treatments of migraine lower plasma glutamate levels. Cephalalgia. 2009; 29: 
423-429.
79. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily 
headaches: field trial of revised IHS criteria. Neurology. 1996; 47: 871-875.
Citation: Gasparini CF, Smith RA and Griffiths LR. Biochemical Studies of the Neurotransmitter Glutamate: A Key 
Player in Migraine. Austin J Clin Neurol 2015; 2(9): 1079.
Austin J Clin Neurol - Volume 2 Issue 9 - 2015
ISSN : 2381-9154 | www.austinpublishinggroup.com 
Griffiths et al. © All rights are reserved
